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Background: Multiple sclerosis is a chronic, incurable, demyelinating disease that requires long-term treatment.
Rates of non-adherence to prescribed therapy of up to 50% have been reported for chronic diseases. Strategies to
improve treatment adherence are therefore of the utmost importance. This study will evaluate the effect of using
electronic and paper diaries on treatment adherence to interferon beta-1b in patients with a first clinical isolated
syndrome (CIS) or relapsing-remitting multiple sclerosis (RRMS). Here we report on the study design and results of
baseline assessments.
Methods: Patients were recruited into a prospective national multicenter cohort study for an observational period
of 2 years. At the start of the study, patients opted to use a digital (DiD) or paper diary (PD) to document
self-administered injections of interferon beta-1b. Adherence to treatment will be assessed on the dropout rate at
the end of the observation period and on the regularity of injections every other day at 6-month intervals.
Patient-related health outcomes will also be evaluated.
Results: 700 patients with a mean age of 38.3 (SD 10.3) years and a mean duration of disease since diagnosis of 3.6
(SD 5.9) years were enrolled. 383 patients opted for the digital diary, 192 of which included an injection reminder.
Significantly more male than female patients opted for the DiD. Only gender was identified as a factor influencing
the decision for DiD or PD. Based on rating scales, a significantly higher proportion of women had depressive
comorbidities at baseline.
Conclusions: Demographic characteristics of the two cohorts were similar at baseline. More women chose a paper
diary, and more had depression at baseline. These imbalances will be addressed in the analysis of the study as
possible confounders influencing long-term treatment adherence in the digital and paper diary cohorts.
Trial Registration: ClinicalTrials.gov Identifier: NCT00902135.
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Multiple sclerosis (MS) is a chronic inflammatory dis-
ease of the central nervous system resulting in functional
deficits due to demyelination and axonal degeneration.
Disease-modifying drugs (DMD) such as interferon
(IFN) beta or glatiramer acetate are the current drugs of
choice for the first-line treatment of MS. As a chronic
disease, MS requires long-term treatment, hence close
adherence to prescribed therapy is a prerequisite for
long-term benefit. Among people with chronic diseases,
low adherence rates to long-term medication are a com-
mon problem, and non-adherence rates of up to 50% on
average have been estimated by the World Health
Organization depending on the disorder [1,2].
As a consequence, enormous costs for healthcare sys-
tems may be created by poor adherence because of re-
lapses, prolonged duration of disease states, hospital
admissions, early retirement, and secondary diseases
[3,4]. Non-adherence rates for MS vary between 6 and
43% depending on factors such as type of study, defin-
ition of non-adherence, type of DMD and individual dis-
ease state [5,6]. Non-adherence of MS patients to their
DMD may be defined as either termination of therapy or
interruption of regular administration. Treatment adher-
ence is influenced by a variety of factors, including fac-
tors related to the MS centre or the patient’s clinical
condition, side effects, involvement in treatment deci-
sions or way of coping [5]. Recent studies revealed that
besides physical and psychological factors, depression,
pain from injection, skin reactions and patient- and
physician-related factors may affect adherence to medi-
cation [5,7]. Tremlett et al. identified lower education
levels, increased alcohol consumption, and history ofDID-r: Digital diary with reminder function
DiD-nr: Digital diary without reminder function
PD:       Paper diary
Figure 1 Study design. After completion of the dose titration phase, patie
were randomly assigned.missed doses as further factors that reduce adherence
[8].
The current DMDs have to be administered regularly
following strict injection schedules. Missing one or more
doses over a given period has been used as a definition
for non-adherence [9,10]. Missing a single injection usu-
ally has no clinical relevance. Interruption of DMD
treatment, however, may result in loss of efficacy and de-
creased treatment benefit [10]. Improvement and main-
tenance of adherence to DMDs is therefore of great
importance in ensuring a positive influence on the
course of disease in MS patients. This means that inter-
ventions intended to enhance medication adherence
have to cover different aspects to achieve overall effect-
iveness, such as providing the patient with detailed in-
formation on treatment, realistic treatment expectations,
convenient care, crisis intervention, optimized support
by nursing services, and counselling [11,12].
One of the most frequent reasons for missing injec-
tions is simply forgetting to administer the medication
[8,10,13,14]. Thus, measures that regularly remind the
patient to administer the medication may help to im-
prove adherence, and ultimately clinical outcome. The
use of an electronic diary may be a way to address this
problem. The use of electronic diaries is well established
in conditions such as haemophilia and migraine [15-17],
but they are not yet in widespread use by MS patients.
They are also a reliable means of supporting self-
monitoring, documentation of relevant symptoms or
side effects, and documenting and assisting disease
management.
The goal of the study described here – the “Betaferon®
injection management: Non-interventional study onnts were enrolled and opted for the DiD or PD. DiD-r and DiD-nr
Figure 2 Picture of the digital diary.
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jection Therapy (BETAPATH)” study – is to compare
treatment adherence to IFN beta-1b (Betaferon®) in CIS-
and RRMS patients under daily-life treatment conditions
using a paper diary (PD) or an electronic diary in the
form of a Personal Digital Assistant (PDA, or digital
diary [DiD]) with and without a reminder function. Here
we report on the design of this study and the findings of
baseline assessments.
Methods
BETAPATH is a national, multicentre, prospective, ob-
servational, non-interventional cohort study in MS pa-
tients in the care of hospital neurological departments
and office practices in Germany. Recruitment lasted
from 05/2009 to 12/2011. 700 patients with CIS or
RRMS, who had started treatment with IFN beta-1b
(Betaferon®), were included. The patients are being
followed up for up to 2 years after the first visit (Figure 1).
They were offered the use of a DiD (Figure 2) or a PD.
Patients who opted for a DiD were randomly assigned a
device with (DiD-r) or without (DiD-nr) an injection re-
minder function. All patients were asked to document
their self-administration of IFN beta-1b, which is ap-
proved for administration every other day in the stand-
ard dosage (8 MIU). Deviations from this injection
schedule were to be documented in the DiD or the PD.
The study was approved by the Ethics Committee of the
Ärztekammer Nordrhein and registered at clinicaltrials.
gov (NCT00902135). All participants had to give writ-
ten informed consent. Quality reviews are being conducted
by an independent contract research organization (CRO)
by telephone and on site-interviews twice during the study
for 5% of the enrolled patients. Sites to be monitored are
selected by the CRO based on a defined composite score.
Adult RRMS and CIS outpatients aged at least 18
years who had completed initial dose titration or started
treatment with IFN beta-1b no longer than 3 months
earlier were invited to participate. Patients were not in-
vited to take part in the study until the decision had
been taken to start them on IFN beta-1b.
The physician or nurse responsible explained to the
patient how to use the DiD. A hotline for questions was
also available. The DiD is a commercially available
Smartphone with all standard and cost functions blocked
(Figure 2). Half of the devices are equipped with an in-
jection reminder. Devices with and without the reminder
function were randomly allocated. All DiDs provide an
injection scheme and document the injection history.
They also make suggestions for suitable injection sites
for upcoming injections, and have a diary and a help
function with information on the administration of IFN
beta-1b. Other injection-relevant details can also be
recorded, such as side effects. The user records everyinjection with the date on the DiD. All entries are trans-
mitted online to a central database maintained by an ex-
ternal service provider. Legal requirements with respect
to confidentiality of patient data are guaranteed.
After the initial visit, follow-up visits are conducted
after 3, 6, 12 and 24 months. Table 1 shows the schedule
of investigations during the study.
The primary outcome measure of adherence to the ther-
apy with IFN beta-1b is overall continuity of treatment.
All patients who discontinue treatment before week 104
for any reason specified in the case report form (CRF) e.g.
an adverse event, withdrawal of informed consent, loss to
follow-up, are classed as dropouts.
The secondary outcome measure of treatment adher-
ence is the overall regularity of IFN beta-1b injections in
relation to the prescribed ‘every other day’ schedule.
Subjects are considered adherent to the injection schedule
if they do not miss more than 5 injections every 6 months
over the 2-year period. Dropouts are considered adherent
to the injection schedule if they are treated for at least 6
months and are adherent to the injection schedule up to
their last visit in this non-interventional study (NIS). For
patients who dropped out for reasons not related to ad-
herence, e.g. loss to follow-up, death, closure of site, ter-
mination of study, adherence is assessed up to the time of
Table 1 Visit schedule
Baseline visit FU visit 1 FU visit 2 FU visit 3 Last visit
Day 1 Month 3 Month 6 Month 12 Month 24
Patient information and informed consent X
Demographics X
Neurological history, clinical events, disease course X X X X X
Disability (EDSS) X X X X X
AEs X X X X
MRI findings if available X X X X X
Medication X X X X X
Cognitive status, PASAT X X X
Patient diary X X X X
CES-D X X X X X
Fatigue Scale (WEIMuS) X X X X X
FAMS X X X X X
EQ-5D X X X X X
Treatment Support Questionnaire X X
FU visit Follow-up visit.
AE Adverse event.
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months in the study.
Other secondary outcome measures include adherence
for each 6-month interval, dropout rates by dropout rea-
son, patient satisfaction and tolerability, also with regard
to the injection devices used, and clinical course, e.g. re-
lapse rate, grade of disability. Patient-related health out-
comes such as depression, cognition, fatigue and qualityTable 2 Demographic characteristics
Total
No. of patients 700
Age [years] - mean (SD) 38.3 (10.3)
Body weight [kg] - mean (SD) 73.6 (15.5)
Men - n (%) 201 (28.7)
Women - n (%) 496 (70.9)
Diagnosis [years] before - mean (SD) 3.6 (5.9)
Relapse rate last two years - mean (SD) 1.6 (1.3)
EDSS - mean (SD) 2.0 (1.4)
Diagnosis CIS - n (%) 35 (5.0)
Diagnosis RRMS - n (%) 662 (94.6)
Living with partner - n (%) 555 (79.3)
Living alone - n (%) 142 (20.3)
Educational status
- Elementary school - n (%) 151 (21.6)
- Secondary school - n (%) 353 (50.4)
- High school - n (%) 121 (17.3)
- University - n (%) 70 (10.0)
1) t-test / 2) Fisher test.of life are also assessed. Safety-related variables consist
of a general tolerability assessment by the physician and
reports of adverse events with an assessment of causal
relationship, seriousness, action taken, and outcome.
Throughout the study, patient-reported outcomes are
documented by the following rating scales FAMS
(Functional Assessment in MS [18], higher scores = bet-
ter outcome), CES-D (Center of Epidemiologic StudiesPD DiD p value
317 383
39.8 (10.6) 37.0 (9.9) 1) p<0.001
71.5 (13.8) 75.3 (16.5) 1) p<0.001
67 (21.1) 134 (35.0) 2) p<0.001
248 (78.2) 248 (64.8)
3.7 (5.8) 3.5 (6.0) 1) p=0.668
1.7 (1.2) 1.6 (1.3) 1) p=0.357
2.1 (1.5) 2.0 (1.4) 1) p=0.149
11 (3.5) 24 (6.3) 2) p=0.117
304 (95.9) 358 (93.5)
261 (82.3) 294 (76.8) 2) p=0.059
54 (17.0) 88 (23.0)
2) p=0.264
75 (23.7) 76 (19.8)
164 (51.7) 189 (49.3)
50 (15.8) 71 (18.5)
26 (8.2) 44 (11.5)
Table 3 Age of study cohorts by previous DMD treatment
Previous treatment Total PD DiD p-value
No
n patients 498 223 275
age [years] - mean (SD) 37.3 (10.4) 38.6 (10.6) 36.3 (10.1) 0.011
Yes
n patients 197 91 106
age [years] - mean (SD) 40.6 (9.7) 42.5 (10.1) 39.0 (9.2) 0.013
p<0.001 for difference in age (previous treatment no vs. yes in
total population).
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siveness), WEIMuS (Würzburger Erschöpfungsinventar
bei MS [22], higher score = more fatigue), EQ5-D
(EuroQuol-5D Health State [23], higher score = better
quality of life) and EDSS (Expanded Disability Status
Scale [24], higher score = more disability).Statistics
Descriptive analysis of the data was performed using
summary statistics for categorical and quantitative (con-
tinuous) data. Continuous data were described by num-
ber of non-missing values, mean, standard deviation,
minimum, median and maximum. Categorical data, in-
cluding categories of continuous data, are presented in
frequency tables.
Significance calculations were performed based on
t-tests for continuous variables, and on χ2-tests or (if pos-
sible) exact Fisher tests for categorical variables. As the
analyses are exploratory, significant p-values <0.05 should
be interpreted as exploratory results. As BETAPATH is a
NIS and analyses are based on an interim database, miss-
ing values may appear for all variables analysed and per-
centages for categorical variables may therefore not add




Total PD DiD p-
valuemean (SD) mean (SD) mean (SD)
FAMS total score 132.4 (29.4) 129.3 (29.5) 134.8 (29.1) 0.027
FAMS-TOI 109.5 (24.5) 106.8 (24.6) 111.5 (24.4) 0.030
CES-D score 13.2 (9.8) 14.1 (10.2) 12.4 (9.4) 0.040
WEIMus total score 20.4 (17.3) 21.2 (17.5) 19.8 (17.2) ns
EQ-5D VAS 74.3 (18.4) 73.0 (18.0) 75.3 (18.7) ns
FAMS Functional assessment in MS.
FAMS-TOI FAMS Trial Outcome Index.
CES-D Center for Epidemiologic Studies Depression Scale.
WEIMuS Würzburger Erschöpfungsinventar bei MS.
EQ5-D VAS EuroQuol 5-D Visual Analogue Scale.
ns non significant.Results
Between May 2009 and December 2011, 700 patients (496
women [70.9%] and 201 men [28.7%]; 3: sex missing) with
CIS (35) or RRMS (662, 3 missing) were enrolled at 164
sites and had baseline documentation. Of these, 317 are
using a PD and the remaining 383 are using a DiD (192
with reminder function, 191 without).
The demographic characteristics of the patient
population on enrolment are summarized in Table 2.
The mean age was 38.3 (SD 10.3) years, and the
mean duration of disease since diagnosis of MS 3.6
(SD 5.9) years. There were no significant differences
between the cohorts (PD, DiD) with respect to dur-
ation of illness, relapse rate, grade of disability
(EDSS), educational level and social status. For age
and body weight, there were small but significant dif-
ferences. While exactly 50% of the women chose the
DiD, a significantly larger proportion of men (66.7 vs
33.3%, p<0.001) opted for the DiD. Most women and
men were living with a partner on enrolment, but
more men than women living alone are using the
DiD (81.8 vs 53.1%, p=0.001). The patients living with
a partner and using a PD are older than those using
a DiD (40.1 vs 37.8 years, p=0.007), but there was no
significant difference for the group living alone.
Of the 700 patients enrolled, 498 (343 women, 155
men) were treatment-naïve for DMDs. Of these 498, 223
opted for a PD and 275 for the DiD. Amongst the latter,
104 were men (37.8%), while there are only 51 men in
the PD group (22.9%, p<0.001). The patients with pre-
treatment with any MS therapy (197, 46 men, 151
women) were significantly older than those without pre-
treatment (Table 3). In both the untreated and the
pretreated groups, the PD users are significantly older
than the DiD users (Table 3).
The duration of disease in the pretreated group was
longer: MS was diagnosed 7.1 years (SD 6.4) before en-
rolment, compared to 2.2 years (SD 5.0) in the treatment-
naïve group. More than 60% of the patients had a history
of MS of less than 2 years, which is reflected in the high
proportion of patients without DMD pretreatment.
The mean EDSS score for all patients enrolled was 2.0
(SD 1.4), with no difference between the PD and DiD
groups.
Patient-reported outcomes assessed by the different
rating scales are summarized in Table 4. The mean
FAMS total and the FAMS-TOI scores were slightly but
significantly higher in the DiD (134.8 and 111.5 respect-
ively) than the PD group (129.3 and 106.8), indicating
better MS-related quality of life in the DiD group. The
total scores of the WEIMuS ranged around 20 and the
mean values for the VAS of the EQ-5D were about 74,
reflecting a low level of fatigue and a relatively high level






























*   p = 0.04 (PD vs DiD total)
** p < 0.001 (men vs. women)
* **
Figure 3 Total CES-D scores stratified by sex of the total population and the PD and DiD cohorts.
Table 5 Grouped CES-D total score at baseline
CES-D Total PD DiD
n (%) n (%) n (%) p-value
Total 593 (100.0) 262 (100.0) 331 (100.0) ns
Missing 35 (5.9) 16 (6.1) 19 (5.7)
0–15 369 (62.2) 153 (58.4) 216 (65.3)
≥16 189 (31.9) 93 (35.5) 96 (29.0)
16–20 66 (11.1) 30 (11.5) 36 (10.9)
21–25 53 (8.9) 28 (10.7) 25 (7.6)
≥26 70 (11.8) 35 (13.4) 35 (10.6)
≥16 defined as cut off for the presence of depressive symptoms.
16-20 slightly depressed; 21-25 moderately depressed, ≥26 severely depressed.
ns = non significant.
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two instruments.
With respect to depressiveness rated on the CES-D
scale, the total score in the PD group was slightly but
significantly higher than in the DiD group. The mean
CES-D score for the total study sample was 13.2 (SD
9.8, range 0–48) and for the PD and DiD subgroups,
14.1 (SD 10.2, range 0–48) and 12.4 (SD 9.4, range
0–43) respectively (Figure 3). Women had a significantly
higher mean value for the CES-D total score (Figure 3).
Within the gender subgroups, however, no significant
differences between the PD and DiD groups were found
(data not shown). The cut-off for the presence of depres-
sive symptoms is ≥16. 62.2% of patients had a score be-
tween 0 and 15 (no depressive symptoms) and 31.9%
had a score ≥ 16. Significantly more women had a score ≥
16 (p<0.001). Amongst all patients, 66 (11.1%) had scores
of 16–20 (slightly depressed), 53 (8.9%) 21–25 (moderately
depressed), and 70 (11.8%) ≥26 (severely depressed)
(Table 5). In these three groups there was a significant
difference between the proportions of women and men
(p=0.001), in particular with more women than men
among the moderately (10.6 (n=45) vs 4.8% (8)) and se-
verely depressed patients (13.9 (59) vs 6.5% (11)). No sig-
nificant differences were found for grouped CES-D scores
between the PD and DiD groups (Table 5). A higher (14.5
vs 12.7; p=0.064) mean CES-D total score was found for
the pretreated subjects. A higher mean total score (14.1 vs
11.7; p=0.016) for the PD than the DiD group was found
for patients without DMD pretreatment, while no differ-
ence was observed in pretreated patients.
In line with these results, the anxiety/depression di-
mension of the EQ-5D health state showed that about
37.6% of the patients were moderately anxious or de-
pressed, 3.0% extremely so, and that 56.7% were notanxious or depressed. The proportion of patients with-
out anxiety/depression was significantly higher in the
DiD group than the PD group (Table 6) and in men
(Figure 4). This difference was even more obvious in pa-
tients without pretreatment: 63.2% (n=158) of the DiD
group had no depression or anxiety and 50.8% (n=95) in
the PD group (p=0.008).
Discussion
Despite many attempts to improve and facilitate the admin-
istration of DMDs for MS patients, e.g. by assistance from a
special MS nurse and auto-injectors, non-adherence to a
prescribed therapy and treatment schedule is still a problem
for the long-term treatment of MS patients. The study
described here is evaluating the influence of a digital diary
(with and without a reminder function) on treatment
adherence to IFN beta-1b in routine clinical practice. In
keeping with the non-interventional nature of the study,
patients decided themselves whether to use a digital or
paper diary to record treatment administration. Careful
Table 6 EQ-5D Health State: anxiety/depression
EQ-5D Total PD DiD p-value
n (%) n (%) n (%)
Total 593 (100.0) 262 (100.0) 331 (100.0) 0.016
Missing 16 (2.7) 10 (3.8) 6 (1.8)
Not anxious or depressed 336 (56.7) 135 (51.5) 201 (60.7)
Moderately anxious or depressed 223 (37.6) 104 (39.7) 119 (36.0)
Extremely anxious or depressed 18 (3.0) 13 (5.0) 5 (1.5)
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will therefore be necessary before analysis of adherence
rates. This will allow for identification and consideration of
possible confounding factors. A special feature of our study
is the randomized distribution of the DiDs with and without
a reminder function. This design will allow the direct assess-
ment of effects of the reminder function on the overall
dropout rate and the regularity of the injection schedule by
comparing the findings in the two study cohorts. Thus, the
present study may result in a further option in addition to
the approaches using injection devices and nurse support
services discussed recently [25].
Our study is a prospective trial with an observation
period of up to two years and a study population of 700 pa-
tients. It is one of the largest single studies focusing on
long-term treatment adherence in MS using a digital diary.
Findings for the characteristics of the study population at
baseline have already been evaluated. Demographic and
baseline findings for educational level, living status, dur-
ation of disease since start of symptoms, number of re-
lapses, EDSS, impairment of upper extremities, visual
impairment, and cognitive assessment did not differ be-
tween the groups using the digital diary (DiD) and theNumber of patients:               men      women
PD          55          206



























Figure 4 State of anxiety or depression assessed using the EQ-5D in mpaper diary (PD). An imbalance in gender distribution was,
however, found showing that male gender was significantly
associated with usage of the DiD, as well as younger age.
We found nothing in the literature to support a greater
preference amongst men for technical devices, and the
demographics of our study population do not explain this
gender effect. Several studies have focused on gender differ-
ences in the use of computers in general [26], and one
study on the use of patient’s electronic personal health re-
cords by physicians [27]. These studies showed that women
are less willing to use computers and that female physicians
are less willing to use electronic tools.
Analysis of psychometric test results at baseline re-
vealed no difference between the study cohorts for
fatigue measured on the WEIMuS scale or for health-
related quality of life assessed on the VAS of the EQ-5D.
The mean scores on the WEIMuS scale of around 20
(maximum 68) are similar to values obtained in healthy
control persons [22], and hence indicate a low level
of fatigue. In line with this, values obtained on the
EQ-5D-VAS of approximately 74 (maximum 100) indi-
cate a high mean quality of life amongst the study popula-










en and women using a PD or DiD.
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PD and DiD groups respectively (maximum 176). Taken
together, these results suggest that a majority of patients
enjoy a high degree of health-related quality of life, which
may be related to age and the relatively short time since
diagnosis of MS of the study population.
Higher values for the PD group were found for the
scores on EQ-5D health state anxiety subscale and the
CES-D depression rating scale. When the total study co-
hort was stratified by gender a higher degree of depressive
symptoms was found in women. However, after further
stratification of the gender cohorts into DiD and PD sub-
groups the CES-D total score was no longer higher in the
PD group suggesting that the association of depression
and preference for PD usage can mainly be explained by
female gender and not by severity of depression. The
mean CES-D total scores for the whole study population
and for men and women ranged between 10.8 and 14.2,
and were therefore below the cut-off of 15, below which
no relevant depressive comorbidities are expected. About
32% of the total study population, however, had a CES-D
total score of ≥ 16, suggesting that a substantial part of
these patients will show some depressive morbidity during
the study [28]. This result is in line with previous evalua-
tions using the CES-D in male and female MS patients
[29], but much lower than in an epidemiological study of
a large community sample in which 42% of the cohort had
clinically significant symptoms [30]. However, the patients
in the latter study had a much higher mean age (49.3
years) and a much longer mean duration of illness (12.5
years). Correspondingly, the mean disability status of this
cohort was higher than in the present population (5.6 for
women and 6.1 for men vs 2.0). Since the severity of ill-
ness as reflected by the grade of disability has been identi-
fied as the greatest factor associated with depressive
symptoms [30], this might be an explanation for the differ-
ent ratios of depressed and non-depressed subjects.
The findings presented here show an association be-
tween depressive symptoms and female gender. This is not
surprising, as depression is about twice as common in
women than in men in the general population [31]. It has
been shown that patients with symptoms of depression are
more likely to discontinue their DMD and that suitable
treatment of their depression may increase adherence [32].
Conclusions
Amongst a large sample of MS patients enrolled into the
non-interventional BETAPATH study, half of the women
and two-thirds of the men chose to document their treat-
ment using an electronic diary and the remainder chose a
traditional paper diary. Demographic characteristics of the
two cohorts were similar at baseline, except with regard to
gender, which emerged as the main distinguishing factor. A
further potential confounder was depression at baseline,which was disproportionately higher in females. Both fac-
tors must be taken into account in the analysis of findings.
Trial status
This NIS is currently in the last year of follow-up
observation.
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